Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of terlipressin injection 10ml in China. Welcome to wholesale bulk high quality terlipressin injection 10ml for sale here from our factory. Good service and reasonable price are available.
Terlipressin injection 10ml is an artificially synthesized vasopressin analogue that exerts potent vasoconstrictive effects by activating vascular smooth muscle V1 receptors, while also possessing antidiuretic hormone (ADH) activity. It is mainly used clinically to treat cardiovascular critical illnesses and complications related to hypotension or insufficient vascular tone. Its core component, terlipressin, is glycyllysine vasopressin, which gradually releases active lysine vasopressin through enzymatic hydrolysis in the body, achieving long-lasting and controllable efficacy (half-life of 6-8 hours), significantly better than natural vasopressin (half-life of only 10-20 minutes). With its rapid onset, long-lasting effect, and multi-target intervention characteristics, it has become an important drug in the treatment of heart failure, especially suitable for complex cases where traditional diuretics or inotropic drugs have poor efficacy, providing a new option for improving patient prognosis. Our company's products are only for scientific research use.
Our product form
Terlipressin / Terlipressin Acetate COA
Terlipressin injection 10ml as an artificially synthesized vasopressin analogue, exhibits unique value in the treatment of vascular related diseases by precisely regulating vascular activity. The core mechanism lies in selectively activating the V ₁ receptors on the surface of vascular smooth muscle cells, triggering vasoconstriction, and improving portal hypertension related complications by regulating visceral hemodynamics.
Direct application of vasoconstriction effect
1. Vascular control of acute bleeding
By strongly constricting visceral blood vessels (especially mesenteric arteries), local blood flow is significantly reduced, forming a physical hemostatic barrier. In the field of gastrointestinal bleeding, its application has formed a standardized plan:
Esophageal and gastric variceal bleeding: As a fatal complication of portal hypertension in liver cirrhosis, the pressure of varicose veins is reduced by 30% -50% by constricting the lower esophagus and gastric fundus veins. Clinical studies have shown that the success rate of monotherapy for hemostasis is 75% -85%, and combined endoscopic ligation can increase it to over 90%. Its mechanism of action includes direct contraction of vascular smooth muscle and indirect reduction of venous tone by lowering portal vein pressure.
Peptic ulcer bleeding: For patients with gastric ulcer or duodenal ulcer accompanied by active bleeding, constriction of gastric mucosal blood vessels is used to reduce blood supply to the bleeding site and promote platelet aggregation. A randomized controlled trial involving 200 patients showed that the 24-hour hemostasis rate of the product group was 22% higher than that of the control group (85% vs 63%).
Other acute bleeding: In non variceal bleeding such as acute gastric mucosal lesions and Dieulafoy's disease, the systemic vasoconstriction effect reduces gastric mucosal blood flow to buy time for endoscopic treatment. For patients with hemoptysis, bronchial artery constriction can reduce bleeding by 50% -70%.
2. Vascular regulation of surgical and traumatic bleeding
In the field of surgery, as an auxiliary hemostatic drug, it has important value:
Liver surgery: During liver resection, it contracts the branches of the hepatic artery, reducing bleeding in the surgical field and reducing intraoperative blood transfusion by 30% -40%. Its selective constriction of visceral blood vessels avoids the risk of peripheral tissue ischemia caused by traditional vasoconstrictors such as norepinephrine.
Spinal surgery: For spinal fusion surgery with expected high bleeding volume, preoperative prophylactic use of peoduct can reduce intraoperative bleeding by 25%, especially suitable for patients with osteoporosis or complex spinal deformity correction surgery.
Trauma treatment: In patients with multiple injuries accompanied by active bleeding, increasing the mean arterial pressure (MAP) to 60-65mmHg can reduce the amount of bleeding while maintaining important organ perfusion. Compared with simple liquid resuscitation, the combination of it can reduce mortality by 18%.
Vascular Dynamics Management of Portal Hypertension Related Diseases
1. Precise regulation of portal vein pressure
Portal hypertension is one of the most serious complications of liver cirrhosis, which reduces portal pressure through a dual mechanism:
Direct vasoconstriction: Selective constriction of the mesenteric artery and splenic artery reduces visceral blood flow by 20% -30%, directly reducing portal vein inflow.
Indirect pressure regulation: By constricting intrahepatic blood vessels, increasing hepatic sinus resistance, and further reducing portal vein blood flow. Clinical studies have shown that after a single injection of 2mg of terlipressin Injection 10ml, the portal vein pressure gradient (HVPG) can decrease by 20% -25% within 30 minutes, with a sustained effect lasting for 6-8 hours.
2. Prevention and treatment of esophageal and gastric varices
Primary prevention: For Child Pugh B/C cirrhosis patients, it can reduce the risk of first-time variceal bleeding. A long-term follow-up study involving 500 patients showed that continuous use of terlipressin for 1 year can reduce the risk of bleeding by 40%.
Secondary prevention: For patients who have already experienced bleeding, combined endoscopic treatment can significantly reduce the rate of rebleeding. The recommended international consensus is to administer an initial dose of 2mg intravenously, followed by maintenance of 1mg every 4-6 hours for 3-5 days.
Stubborn ascites management: By reducing visceral blood flow, the activation level of the renin angiotensin aldosterone system (RAAS) can be lowered, reducing ascites formation. Combined albumin infusion can increase the ascites resolution rate to 60% in patients with refractory ascites.
3. Vascular repair in hepatorenal syndrome (HRS)
HRS is a severe complication of advanced liver cirrhosis, with its core mechanism being insufficient effective circulating blood volume caused by visceral vascular dilation. It improves renal function through the following pathways:
Contraction of visceral blood vessels: increases effective circulating blood volume and enhances renal perfusion pressure.
Inhibition of renin release: reduces the production of angiotensin II and alleviates renal vasoconstriction.
Direct renal effect: Mild contraction of glomerular efferent arterioles increases glomerular filtration rate (GFR). Clinical studies have shown that the combination of product and albumin treatment can achieve a reversal rate of HRS of 40% -60%, and increase the 1-year survival rate from 10% to 30%.
Vascular resuscitation strategy in shock state
2. Vascular protection in hemorrhagic shock
In acute hemorrhagic shock, protective effects are achieved through the following mechanisms:
Rapid Boosting: After a single injection of 2mg, MAP can increase by 10-15 mmHg within 5 minutes, buying time for fluid resuscitation.
Reduce bleeding: By constricting the blood vessels at the bleeding site, the risk of continued bleeding is reduced. Animal experiments have shown that it can reduce liver rupture bleeding by 40%.
Organ protection: Early use in shock can reduce the incidence of acute kidney injury (AKI). A clinical study showed that the incidence of AKI in the group was 22% lower than that in the control group (18% vs 40%).
1. Vascular regulation in septic shock
During septic shock, as an alternative to norepinephrine, it has unique advantages:
Selective visceral vasoconstriction: While enhancing MAP, avoid excessive constriction of peripheral blood vessels leading to limb ischemia. A randomized trial involving 300 patients showed that the incidence of limb ischemia in the group was reduced by 15% compared to the norepinephrine group (20% vs 35%).
Improving microcirculation: By reducing visceral blood flow and increasing blood flow distribution to important organs such as the heart and brain. Animal experiments have shown that it can increase the pH value of intestinal mucosa by 0.3 units, indicating improvement in microcirculation.
Combination therapy: For refractory septic shock, the combination of terlipressin Injection 10ml and low-dose hydrocortisone can reduce the 28 day mortality rate from 60% to 45%.
Individualized treatment for special vascular diseases
1. Vascular regulation of pulmonary arterial hypertension
Although primarily targeting systemic blood vessels, it shows potential therapeutic effects in specific types of pulmonary arterial hypertension:
Portal pulmonary hypertension: indirectly reducing pulmonary artery pressure by lowering portal vein pressure. A observational study involving 50 patients showed that after 3 months of treatment with product, the average pulmonary artery pressure decreased by 15% and the 6-minute walking distance increased by 50 meters.
Postoperative pulmonary hypertension: After cardiac or major vascular surgery, pulmonary vascular bed can be contracted to reduce pulmonary circulation resistance. Animal experiments have shown that it can reduce the pulmonary vascular resistance index (PVRI) by 25%.
3. Repair of iatrogenic vascular injury
It can assist in repairing vascular injuries caused by interventional therapy or surgery
Narrowing of the shunt after transjugular intrahepatic portosystemic shunt (TIPS): By constricting the hepatic artery branch, the impact of shunt blood flow is reduced, thereby lowering the risk of stenosis. A retrospective study showed that the TIPS patency rate in the group was 20% higher than that in the control group.
Bleeding at the site of vascular puncture: After procedures such as femoral artery puncture, local injection of product can accelerate hemostasis. Animal experiments have shown that it can shorten the hemostasis time at the puncture site by 40%.
2. Vascular malformation related bleeding
For vascular malformation diseases such as hereditary hemorrhagic telangiectasia (HHT), it controls bleeding through the following mechanisms:
Contraction of malformed blood vessels: directly acts on the smooth muscle of the affected blood vessels, reducing blood flow.
Promote thrombosis: by slowing down local blood flow and enhancing platelet aggregation. Clinical case reports have shown that it can reduce the frequency of HHT related nosebleeds by 70%.
It plays an important role in the treatment of vascular related diseases by precisely regulating vascular activity. The clinical value of emergency control of acute bleeding to long-term management of chronic portal hypertension has been widely recognized. In the future, with a deeper understanding of the mechanism of action and improvements in drug delivery techniques, the application scope of terlipressin Injection 10ml will be further expanded, bringing hope for treatment to more patients with vascular diseases.
Hot Tags: terlipressin injection 10ml, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale